A clinical trial has found that a new type of botulinum toxin may have potential as a non-surgical cosmetic treatment
The toxin, Reloxin, was well tolerated in a trial involving 1,200 patients, the majority of whom completed the 13-month study, and the effects were noticeable over 13 months.
Patients received five injections of the new botulinum toxin into their forehead at the start of each treatment cycle and were interviewed seven days later, followed by clinical checks on at least a monthly basis.
Only one patient discontinued the study because of adverse events, which included headaches and drooping of the eyelid or brow.
Publishing their findings in the Archives of Facial Plastic Surgery, the researchers concluded that the treatment takes effect in as little as 24 hours and that between 93 and 95 per cent of patients noticed a difference.
Ronald Moy, lead author and professor at the University of California, Los Angeles, told Bloomberg reporters: "The results of the study show that it's as good as Botox. The side-effects are the same as Botox. Many of our patients liked it even better."